To include your compound in the COVID-19 Resource Center, submit it here.

Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that a greater proportion of patients receiving 320, 480 and 640 µg subcutaneous Locteron every other week achieved

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE